Skip to main content

Table 2 Grade of adverse events in the patients receiving CAR T cells infusion

From: A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy

Patient no.

1

2

3

4

CRS

3

0

1

1

Neurologic events

    

 Depressed level of consciousness

1

   

 Dysphasia

1

   

 Tremor

1

   

Hematologic events

    

 Thrombocytopenia

4

  

1

 Anemia

3

 

2

1

 Neutropenia

4

1

4

3

Other non-hematologic events

    

 Diarrhea

  

1

 

 Fever

2

 

2

2

 Vomiting

   

1

 Nausea

   

1

 Muscle or bone pain

1

   

 Infection

3

3

3

3

 Hypotension

2

1

 

1

 Elevated aminotransferases

   

1

 Elevated blood bilirubin

2

1

 

2

 Hypokalemia

1

1

  

 Hypocalcemia

1

 

1

2

 Hypoalbuminemia

2

  

1

 Hypofibrinogenemia

3

   

 Prolonged APTT

1

 

1

Â